BC
TGTX icon

Bridgefront Capital’s TG Therapeutics TGTX Stock Holding History

Bridgefront Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,509
Closed -$286K – 611
2023
Q2 		$286K Buy
+11,509
New +$297K 0.15% 266
2023
Q1 		– Sell
-44,279
Closed -$524K – 591
2022
Q4 		$524K Buy
44,279
+24,434
+123% +$177K 0.37% 87
2022
Q3 		$117K Buy
+19,845
New +$130K 0.12% 269

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bridgefront Capital's TGTX Position: Q3 2023 in Review

Bridgefront Capital sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 11,509 shares — an estimated $286K sold.

Bridgefront Capital first reported a position in TGTX in Q3 2022 and held it in 3 quarters. The position peaked at $524K in Q4 2022. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Bridgefront Capital reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Bridgefront Capital sold 11,509 TG Therapeutics shares in Q3 2023, an estimated $286K.
  • Bridgefront Capital first reported a position in TG Therapeutics in Q3 2022 and held it in 3 quarters.
  • Bridgefront Capital's TG Therapeutics position peaked at $524K in Q4 2022.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Bridgefront Capital's 13F filing for Q3 2023, filed 14 Nov 2023.